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Abstract: Clinical research on herbal-based dentifrice +/− mouth rinse products is very limited
compared with the plethora of research on conventional oral care products under normal oral hygiene
conditions. The aim of this study was to determine the anti-inflammatory effects of a novel plant
Carica papaya leaf extract (CPLE) on interdental bleeding in healthy subjects. In this randomized,
single-blind parallel-design study, the eligible subjects were generally healthy non-smokers,
aged 18–26, who exhibited healthy periodontal conditions upon study entry. The participants were
equally randomized into the following four groups: CPLE dentifrice, CPLE dentifrice and mouthwash,
sodium lauryl sulfate (SLS)-free enzyme-containing dentifrice and SLS-free enzyme-containing
dentifrice with essential oil (EO) mouthwash. Subjects were instructed to brush their teeth twice a
day without changing their other brushing habits. Interdental bleeding (BOIP) was measured from
inclusion (T0) until the fourth week (T4) of the study. Clinical efficacy was assessed after one, two,
three and four weeks of home use. The analyses compared BOIP between groups and were then
restricted to participants with ≥70% and then ≥80% bleeding sites at T0. Pairwise comparisons
between groups were performed at T0 and T4, and a logistic regression identified correlates of gingival
bleeding (T4). Among 100 subjects (2273 interdental sites), the median percentage of bleeding sites per
participant at T0 was 65%. The bleeding sites dramatically decreased in all groups between T0 and T4
(relative variations from−54% to−75%, p < 0.01 for all). Gingival bleeding did not significantly differ
between the CPLE dentifrice and the SLS-free dentifrice +/− EO mouthwash groups (from p = 0.05
to p = 0.86), regardless of the baseline risk level. Among the CPLE dentifrice users, fewer bleeding
sites were observed when toothpaste and mouthwash were combined compared to bleeding sites in
those who used toothpaste alone (21% vs. 32%, p = 0.04). CPLE dentifrice/mouthwash provides an
efficacious and natural alternative to SLS-free dentifrice +/−EO-containing mouthwash when used
as an adjunct to mechanical oral care to reduce interdental gingival inflammation.
Keywords: biofilm; anti-inflammatory; Carica papaya; interdental bleeding; natural dentifrice;
sodium lauryl sulfate free dentifrice; mouthwash; essential oils
Int. J. Environ. Res. Public Health 2018, 15, 2660; doi:10.3390/ijerph15122660 www.mdpi.com/journal/ijerph
Int. J. Environ. Res. Public Health 2018, 15, 2660 2 of 16
1. Introduction
The self-realized mechanical disruption of biofilm with tooth brushing and interdental tooth
brushing is the best prevention method currently to prevent and reduce gingival inflammation [1].
This mechanical action is insufficient without the use of chemical products as dentifrices.
Chemicals agents, such as triclosan, sodium lauryl sulfate (SLS), and propylparaben, and allergens
such as methylisothiazolinone and methylchloroisothiazolinone, as well as chlorhexidine, have been
added to dentifrices to reinforce their antibacterial action. These products can pose a human health
risk [2–5]. Some of these substances show undesirable side effects, such as altered taste and tooth
staining, and doubts persist regarding detrimental impacts on endocrine function, notably, fertility [6,7].
Some manufacturers have moved away from SLS, chlorhexidine and triclosan and introduced
other, less irritating surfactants such as non-ionic polyethylene glycol ethers of stearic acid [8,9].
Likewise, enzyme-containing dentifrices, such as Zendium®, Enzycal®, and Jason Powersmile
Toothpaste®, which are free of SLS, chlorhexidine and triclosan, have also been developed as
alternatives to dentifrice chemotherapeutic agents. Antimicrobial agents present in dentifrices cannot
effectively penetrate hard-to-reach areas in the oral cavity, resulting in biofilm-dwelling bacteria
accumulation in the interdental spaces [10,11]. In this sense, mouthwashes for daily use are a
complement to brushing to improve oral health [12,13].
It is necessary to distinguish solutions to be used daily, after or before brushing of the teeth,
from those with a therapeutic aim, which often have the status of a drug and whose use must
be much more punctual. These therapeutic solutions are usually prescribed following oral surgery,
tooth extraction or device-related injury [14,15]. Due to the high dose of chlorhexidine (0.2% minimum),
these therapeutic solutions are also are good antiseptics. The effects of an alcohol vehicle solution
versus an essential oil (EO) mouthwash (for example thymol, menthol, eucalyptol and methyl salicylate)
as daily mouthwashes in relation to antiplaque and antigingivitis properties have been discussed [16].
An unanswered question is whether toothpastes and mouthwashes used in combination have a
significant effect on inflammation parameters, without causing any interference regarding their
inhibitory effects on plaque, regardless of the order of use [17].
More consumers are using natural health products in the modern world [18]. In recent years,
natural compound (excluding EO)-containing mouthwashes have shown a growth in demand in
markets and the professional community [19]. A growing number of dentists have embraced
the philosophy that natural agents are better for the oral health of children and the general
population [20]. Given the increased bacterial resistance to antibiotics currently used in dentistry,
natural compounds are important for the prevention of oral bacterial growth, adhesion and
colonization [21]. Herbal medicines, including herbs, herbal materials, herbal preparations,
finished herbal products that contain parts of plants or other plant materials as active ingredients,
and various medicinal plants, individually or in combination, have been used for over 2000 years
to maintain oral hygiene and to prevent inflammation [22–24]. An overview of representative
plant extracts found that they have favorable antimicrobial properties against oral bacteria [25].
Side-effect-free medicinal herbs–Acacia chundra Willd, Adhatoda vasica Nees, Mimusops elengi L.,
Piper nigrum L., Pongamia pinnata (L.) Pirerre, Quercus infectoria Oliv, etc.—might supplement or even
be a substitute for conventional anti-infectious agents in the battle against periodontitis and other
biofilm-related diseases [26–28]. The antimicrobial properties of herbal dentifrices and mouthwashes
vary greatly; however; few of these products have undergone rigorous testing, as evidenced by the
limited amount of information on their safety and efficacy in the literature [29].
Dentifrices labelled as “natural” typically do not include ingredients such as synthetic sweeteners,
artificial colors, preservatives, additives, or synthetic flavors and fragrances [30]. Clinical research on
herbal-based mouth rinses and dentifrices is very limited, whereas a plethora of research exists on
conventional oral care products [27]. Among these products, natural dentifrices/mouthwashes, in the
form of water mixed with a powder containing Carica papaya leaf extract (CPLE) have been recently
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marketed in Europe (Gencix®). However, to the best of our knowledge, there have been no studies
investigating the anti-inflammatory action of CPLE.
The main objective of this study was to compare the efficacy in reducing interdental gingival
bleeding between a natural dentifrice/mouthwash containing CPLE and a classical SLS-free
enzyme-containing dentifrice, alone or associated with an EO mouthwash.
2. Materials and Methods
2.1. Study Design
The study was designed as a single-blind, four-group, randomized, controlled, parallel clinical
trial. The guidelines of the CONSORT Statement were followed. The study protocol was reviewed and
approved by the Institutional Ethics Board Committee on research involving humans, Dental Faculty,
University of Granada, Spain. Written informed consent in agreement with the Declaration of Helsinki
was obtained from all enrolled individuals. Clinical Trials Registry—2018-000905-22. Registered 28
February 2018 (retrospectively registered).
The eligible volunteer participants were randomly assigned to one of the four experimental
groups, each of which included 25 participants using a random number generator (www.random.org).
To achieve the same sample size in both groups and simultaneously satisfy the randomization
procedure to achieve balanced groups with respect to the most relevant variables (sex and baseline
bleeding), a stratified (two levels for sex and two levels for baseline bleeding) block randomization
(computer-assisted) method was used. Baseline bleeding was defined as the percentage of bleeding
sites per participant as follows: a high level of bleeding if the participant had ≥30% bleeding sites and
a low level of bleeding if the participant had <30% bleeding sites [31]. Each participant was identified
using a code. The methods were not changed after the trial began.
2.2. Participants
The source population consisted of voluntary healthy subjects aged 18–26. The respondents
were assured that participation was voluntary. One hundred and forty-one persons volunteered to
participate in the study. All of the candidates were screened for suitability by the research team.
The subjects who met the following inclusion criteria were included in this study. The selection
inclusion criteria were (i) 18–26 years old; (ii) good general health and not pregnant or breastfeeding;
(iii) the presence of at least 20 natural teeth (excluding 3rd molars); (iv) non-smokers; (v) willing to give
written formed consent; (vi) capable of following the study for a period of 4 weeks; (vii) no allergy to
personal care products or their ingredients; (vii) willing to abstain from the use of interdental brushing
devices (interdental brushes, dental floss, etc.) during the study; (ix) no implants or orthodontic
appliances; (x) willing to refrain from the use of brushing supplements containing antibacterial agents
such as amine fluoride, chlorhexidine, silver ions, etc. during the study; and (xi) brushing the teeth at
least twice per day.
The exclusion criteria were (i) subjects unable or unwilling to sign the informed consent form,
(ii) unable to answer questions, (iii) non-cooperative, (iv) a state of health that requires premedication
before visits or dental procedures, (v) subjects with the following pathologies: diabetes, haemophilia,
anticoagulant treatment, and risk for infectious endocarditis, (vi) the presence of moderate or advanced
periodontal disease, (vii) 2 or more decayed teeth during the screening or other diseases of the hard or
soft oral tissues, (viii) use of drugs that affect salivary flow, (ix) use of antibiotics or antimicrobial drugs
within 30 days prior to the study visit, (x) participation in any other clinical study in 1 week prior to
enrolment in this study, (xi) subjects requiring dental treatment or other oral prophylaxis during the
study dates, (xii) allergy to dentifrice ingredients, (xiii) allergy to several mouthwash components,
(xiv) the presence of an orthodontic appliance, (xv) a history of allergy to natural remedies such as
herbal ingredients, (xvi) immune deficiencies, (xvii) smokers (daily consumption greater than or equal
to 1 cigarette), (xviii) regular use (more than once a week) of interdental brushes or dental floss in
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addition to dental brushing, (xix) regular (more than once a week) use of a mouthwash and (xx)
subjects requiring geographical mobility. All eligible volunteers were given oral information about
the products and the purpose of the study. All subjects could at any time withdraw from the study.
The study flow chart is shown in Figure 1.Int. J. Environ. Res. Public Health 2018, 15, x FOR PEER REVIEW  4 of 16 
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Figure 1. Flow chart of the study.
2.3. Interventions
The study was conducted in the Division of Prevention, Dental Clinic, University of Granada,
Spain. At baseline, April 2017, the prescreened participants were referred to the clinic for examinations
(gingivitis, periodontal conditions, and bleeding). A colorimetric probe (IAP Curaprox; Curaden,
Kriens, Switzerland) was used to evaluate the diameter of the interproximal spaces, except those
between the second and third molars, to determine the appropriate size of the interdental brushes (IDBs)
for each site [32]. After the baseline oral examinations and assessments of the other inclusion/exclusion
criteria, the qualifying participants were randomly assigned to one of the following four groups
(Figure 1): (i) Group G: test CPLE dentifrice; (ii) Group G + M: test CPLE dentifrice with CPLE
mouthwash; (iii) Group Z: control with SLS-free enzyme-containing dentifrice; (iv) Group Z + L:
control with SLS-free enzyme-containing dentifrice and alcohol-based EO mouthwash.
All participants were provided with sufficient amounts of their assigned products. They were
asked to brush for the total duration of the study twice daily for 2 min using only their provided
toothbrush and assigned dentifrice/mouthwash. Groups G + M and Group Z + L were directed to use
20 mL of CPLE or alcohol-based EO mouthwash twice a day for 30 s after tooth brushing. The first
rinse and rinses on the examination visits occurred under supervision at the study site. All other
rinsing was unsupervised. Subsequent rinsing with water was not allowed. The use of any other
dental products or interdental cleaning aids during the study was not allowed.
2.4. Description of Dentifrices and Mouthwashes
The CPLE dentifrice and mouthwash were used after dilution of the powder in water.
The powder contained an aqueous extract of Carica papaya leaves (40%) with pumice (60%)
(Gencix®, Esprit d’Ethique, Orvault, France).
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The SLS-free enzyme-containing dentifrice contained sodium fluoride, colostrum, lactoperoxidase,
lysozyme glucose oxidase and amyloglucosidase (Zendium® classic, Sara Lee, Amersfoort,
The Netherlands).
The alcohol-based EO mouthwash contained eucaliptol (0.092%), menthol (0.042%), methyl
salicylate (0.060%), and thymol (0.064%) as active ingredients. Inactive ingredients included water,
alcohol (21.6%), benzoic acid, poloxamer 407, benzoic acid, and flavoring (Listerine® Cool Mint®,
Manufacturer Johnson & Johnson Healthcare Products, Maidenhead, UK).
2.5. Assessment and Outcome
All selected individuals were followed after the inclusion visit (T0) for 4 weeks with the following
weekly dental consultations: Week 1 (T1), Week 2 (T2), Week 3 (T3) and Week 4 (T4). These consultations
involved the visual assessment of interdental gingival bleeding and supragingival plaque (PI) by a
trained and calibrated dental examiner.
Gingivitis was assessed using the Bleeding on Interdental Brushing Index (BOIP) on the interdental
space. All interdental sites were recorded, as was the bleeding response to the horizontal pressure
applied in the interdental area by a calibrated IDB. After 30 s, bleeding at each gingival unit was
recorded according to the following scale: 0, absence of bleeding; and 1, bleeding. The probing
protocol was always the same, starting in the 16–17 interdental space and finishing in the 46–47
interdental space.
At each visit during the evaluation period, a calibrated interdental brush was introduced into the
interproximal space, and the presence of bleeding was observed. The pressure applied by a horizontal
brush in the interdental area should be firm and continuous until reaching maximum compression
with minimal discomfort to the patient. The pressure used to place the IDB was approximately
50–100 N·cm−2 (0.20–0.40 gram-force), and 83% of participants were assigned a Visual Analogue Scale
score of ≤1. More details can be found in a previous study [31].
The plaque score was assessed using a standard scale called the Turesky Modification of the
Quigley Hein Plaque Index after disclosing and scored from 0 to 5, where 0 = no plaque, 1 = separate
flecks or a discontinuous band of plaque at the gingival (cervical) margin, 2 = a thin (up to 1 mm),
continuous band of plaque at the gingival margin, 3 = a band of plaque wider than 1 mm but less than
1/3 of the surface, 4 = plaque covering 1/3 or more, but less than 2/3, of the surface, and 5 = plaque
covering 2/3 of more of the surface [33].
The primary efficacy endpoint was the percentage of bleeding sites at four weeks, and the
secondary endpoints included the mean BOIP at one, two and three weeks and the mean PI at one,
two, three, and four weeks.
2.6. Sample Size Calculation
The calculation of the sample size (interdental sites) was performed using Sample Power 2.0
(SPSS, Chicago, IL, USA) software. A t-test for independent groups was used to detect a power of 80%
and 5% alpha error for an estimated Cohen’s d of 0.5, a medium effect size according to Cohen’s scale,
for bleeding after interdental brush use.
We required 256 a-priori interdental sites (64 per group, 4 groups). After considering a design
effect (owing to interdental sites being clustered within participants) of 5.0 (estimated from previous
experience with these IDBs) in estimating the bleeding percentage, the sample size increased to 1280
interdental sites (=256 × 5). Furthermore, after considering that an estimated 80% of the interdental
sites would be available for analysis (i.e., 20% would be excluded owing to lack of space to introduce
the IDB, the presence of diastema or missing teeth), the sample size increased to 1600 interdental sites
(=1280/0.80). Considering 26 a-priori interdental sites per participant, this resulted in a minimum
sample size of 61 participants (i.e., approximately 15 participants per group).
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2.7. Data Analysis
The output variable is the level of interproximal bleeding at the interproximal site after one
of four commercially available dentifrices/mouthwashes. The statistical unit was the individual
interdental site with the available BOIP measurement. After the preliminary descriptive analyses, the
proportion of the individual bleeding interdental sites among the treatment groups was compared.
Standard errors (se) were calculated according to Dubey and colleagues’ method [34]. In parallel,
relative changes in the proportion of bleeding sites from T0 to T4 were assessed within each group.
All p-values were corrected for complex sampling (multiple interdental sites within the mouth).
Then, analyses were further conducted after restricting the data to subjects with ≥70% of bleeding
interdental sites (median value). In this analysis, we used pairwise univariate comparisons, conducted
weekly from baseline (T0) until the 4th week (T4). The statistical methods are indicated in the table
footnotes. Given the possible loss of comparability of the randomized groups due to the restriction,
a multivariate multilevel logistic model was computed at T4, investigating the risk of interdental
bleeding as a dependent variable with treatment group (G vs. Z) as the main explanatory variable.
Descriptive statistics (p-values and standard errors) were performed with SPSS Windows 20.0 (IBM Inc.,
Chicago, IL, USA) for analyses based on the patients. The SUDAAN 7.0 (RTI, RTP, NC) was used
to account for clustering (multiple interproximal spaces within the patient) for analyses based on
interproximal spaces. The statistical methods are indicated in the table footnotes.
3. Results
3.1. Baseline Characteristics
3.1.1. Subject Characteristics
Of the 141 subjects that volunteered, 33 were excluded based on the eligibility criteria.
Eight participants dropped out for reasons unrelated to the study protocol (Figure 1). In total,
100 participants (47 males, 53 females) completed all visits of this clinical trial and had a mean
age of 23.2 (±3.0) years (range: 19–33 years). All clinical parameters were normally distributed.
The mean proportion of interdental bleeding sites per subject at baseline ranged from 62 to 69% in the
different groups. The median proportion of bleeding sites per subject was close to 65% (Table 1). At the
sampling site level, the overall plaque indexes for groups G, Z, G + M and Z + L were 0.82 ± 0.19;
0.90 ± 0.21; 0.87 ± 0.19 and 0.76 ± 0.30, respectively. There was no significant difference in plaque
accumulation among the four groups or the four timepoints. The mean clinical attachment loss (CAL)
values (mm) were 1.45 ± 0.20; 1.37 ± 0.24; 1.60 ± 0.32 and 1.54 ± 0.38 (p > 0.05), respectively. No safety
issue was noticed for any patient throughout the study period.
Table 1. Distribution of subject characteristics at baseline (n = 100).
Variable Group G(N = 25)
Group Z
(N = 25)
Group G + M
(N = 25)
Group Z + L
(N = 25)
Global
p-Value
Sex, N (%) 0.932 a
Male 11 (44.0) 13 (52.0) 12 (48.0) 11 (44.0)
Female 14 (56.0) 12 (48.0) 13 (52.0) 14 (56.0)
% Bleeding sites, mean ± sd 66 ± 20 63 ± 26 69 ± 22 62 ± 27 0.759 b
Subject Bleeding, N (%)
≥30% Bleeding sites 23 (92.0) 22 (88.0) 24 (96.0) 22 (88.0) 0.719 a
≥70% Bleeding sites 12 (48.0) 11 (44.0) 15 (60.0) 12 (48.0) 0.700 a
a Chi-square test. b Analysis of variance.
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3.1.2. Interdental Sites
Of the 2600 a-priori interdental sites available (i.e., 100 subjects × 26 interproximal sites/subjects),
13 were excluded due to lack of space to introduce an IDB, 28 for missing teeth and 286 for diastema,
leaving a total of 2273 interdental sites available for the analyses (Figure 1). The distribution
of interdental sites according to location was upper-posterior (n = 752, 33.1%), lower-posterior
(n = 757, 33.3%), upper-anterior (n = 392, 17.2%) and lower-anterior (n = 372, 16.4%). According to
the IDB diameter, the distributions were 1.1 mm (n = 88, 3.9%), 0.9 mm (n = 284, 12.5%), 0.8 mm
(n = 589, 25.9%), 0.7 mm (n = 720, 31.7%) and 0.6 mm (n = 592, 26.0%). There were no significant
differences among the groups for the site location (p = 0.30) or the IDB diameter (p = 0.35, p-values
calculated with chi-square test, corrected for multiple sites within the patients with CROSSTAB in
SUDAAN 7.0).
3.2. Inferential Analyses
3.2.1. Changes in Gingival Bleeding in Each Group from T0 to T4
A salient monotonous decrease in bleeding of interdental sites was observed between T0 and T4
in subjects from all groups, regardless of the baseline interdental bleeding level (Figure 2). Overall,
the proportion of bleeding sites per subject substantially decreased in all groups from −59% to −72%,
(p < 0.01 for all), although this trend was more pronounced in Group G + M (Table 2).
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Figure 2. Evolution of interproximal bleeding by group in 2273 interdental sites (100 subjects). Group G:
test Carica papaya leaf extract (CPLE) dentifrice; Group G + M: test CPLE dentifrice with CPLE
mouthwash; Group Z: control with sodium lauryl sulfate (SLS)-free enzyme-containing dentifrice;
Group Z + L: control with SLS-free enzyme-containing dentifrice and alcohol-based essential oil
mouthwash; T0: basal; T1: 1 week; T2: 2 weeks; T3: 3 weeks; T4: 4 weeks.
After restricting the analysis to patients with ≥70% bleeding sites at T0, the magnitude of the
decrease from T0 to T4 was slightly higher in all groups (from −54% to −65%, p < 0.01 for all, Table 3).
Interestingly, the proportional decrease in bleeding interdental sites over the four-week period tended
to be slightly greater in subjects with 70% or more bleeding sites at baseline compared with that of the
overall study population.
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Table 2. Interproximal bleeding after IDB (interdental brush) according to treatment group in 2273 interproximal sites a (from 100 patients).
Time Group G Group Z Group G + M Group Z + L Paired Comparisons (p-Value) c
n %± se b ↓ c n %± se b ↓ c n %± se b ↓ c n %± se b ↓ c Z-G GM-G ZL-G Z-GM ZL-GM ZL-Z
T0 (Baseline) 583 67 ± 4 x 548 62 ± 5 w 575 69 ± 4 w 567 63 ± 5 v 0.45 0.66 0.61 0.26 0.39 0.84
T1 (1 week) 44 ± 4 y 43 ± 5 x 42 ± 4 x 47 ± 4 w 0.91 0.80 0.56 0.92 0.43 0.53
T2 (2 weeks) 30 ± 4 z 31 ± 4 y 35 ± 3 y 37 ± 4 x 0.85 0.34 0.21 0.52 0.62 0.33
T3 (3 weeks) 29 ± 3 z 29 ± 4 y 29 ± 3 y 33 ± 5 xy 1.00 0.99 0.43 0.99 0.43 0.48
T4 (4 weeks) 25 ± 3 z 24 ± 4 z 19 ± 2 z 26 ± 4 z 0.85 0.15 0.83 0.31 0.13 0.71
Effect. T4, % (95%-CI) e 63 (53–72) 61 (47–75) 72 (63–82) 59 (45–73)
a 100 patients × 26 interproximal sites/patient = 2600 interproximal sites. We excluded 13 for lack of space to introduce an IDB -interdental brush-, 30 for missing teeth and 284 for
diastema, leaving 2273 for the analysis (i.e., with enough interproximal space to introduce the IDB). b Standard errors (se) corrected for complex sampling (multiple interproximal spaces
within the mouth) with DESCRIPT procedure in SUDAAN 7.0. c Paired comparisons were calculated correcting for complex sampling, i.e., with DESCRIPT in SUDAAN. Different letters
indicate significantly (p < 0.05) different groups. d p-values corrected for complex sampling (multiple interproximal spaces within the mouth), by using DESCRIPT procedure in SUDAAN
7.0. e Percent difference between T4 and T0 = [((T0 − T4)/T0) × 100], with 95%-CI calculated according to Dubey et al. [2].
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Table 3. Interproximal bleeding after IDB (interdental brush) according to patient’s baseline gingival bleeding and treatment group in 2273 interproximal spaces (from
100 patients).
Patient’s Bleeding Time Group G Group Z Group G + M Group Z + L Paired Comparisons (p-Value) c
n %± se a ↓ b n %± se ↓ c n %± se ↓ c n %± se ↓ Z-G GM-G ZL-G Z-GM ZL-GM ZL-Z
Patient’s Bleeding <70% (50 Patients, with 1119 Spaces)
T0 (Baseline) 297 51 ± 4 x 322 46 ± 5 x 216 46 ± 5 x 284 40 ± 5 x 0.43 0.47 0.09 0.98 0.42 0.42
T1 (1 week) 44 ± 4 x 39 ± 5 x 32 ± 6 xy 36 ± 5 x 0.78 0.25 0.45 0.36 0.66 0.62
T2 (2 weeks) 30 ± 4 y 27 ± 5 y 30 ± 5 y 25 ± 4 y 0.94 0.75 0.74 0.68 0.50 0.79
T3 (3 weeks) 29 ± 3 y 22 ± 5 y 20 ± 3 z 21 ± 4 y 0.56 0.36 0.44 0.80 0.94 0.87
T4 (4 weeks) 25 ± 3 y 20 ± 4 y 16 ± 5 z 19 ± 4 y 0.70 0.77 0.86 0.56 0.68 0.83
Effect. T4, % (95%-CI) d 65 (52–78) 56 (36–77) 65 (43–86) 54 (33–74)
Patient’s Bleeding≥70% (50 Patients, with 1145 Spaces)
T0 (Baseline) 286 84 ± 2 x 226 85 ± 4 w 359 84 ± 2 w 283 87 ± 3 w 0.74 ≈1 0.38 0.75 0.40 0.72
T1 (1 week) 46 ± 5 y 48 ± 9 x 48 ± 4 x 58 ± 5 x 0.84 0.72 0.09 0.97 0.14 0.32
T2 (2 weeks) 34 ± 5 z 38 ± 8 y 38 ± 3 y 50 ± 6 y 0.62 0.44 0.03 0.98 0.07 0.22
T3 (3 weeks) 32 ± 4 z 39 ± 7 y 34 ± 4 y 46 ± 7 y 0.42 0.76 0.08 0.56 0.13 0.48
T4 (4 weeks) 32 ± 5 z 30 ± 7 z 21 ± 3 z 33 ± 6 z 0.77 0.04 0.89 0.25 0.05 0.70
Effect T4, % (95%-CI) 62 (51–72) 65 (48–82) 75 (68–82) 62 (48–75)
a Standard errors (se) corrected for complex sampling (multiple interproximal spaces within the mouth) with DESCRIPT procedure in SUDAAN 7.0. b Paired comparisons were
calculated correcting for complex sampling, i.e., with DESCRIPT in SUDAAN. Different letters indicate significantly (p < 0.05) different groups. c p-values corrected for complex sampling
(multiple interproximal spaces within the mouth), by using DESCRIPT procedure in SUDAAN 7.0. d Percent difference between T4 and T0 = [((T0 − T4)/T0) × 100], with 95%-CI calculated
according to Dubey et al. [2].
Int. J. Environ. Res. Public Health 2018, 15, 2660 10 of 16
3.2.2. Risk of Interdental Bleeding between Treatment Groups
Overall, we did not observe any significant difference between Group G and Group Z or
Group Z+L in terms of a reduction in gingival bleeding over the four-week period (Table 2). In the
subgroup presenting with ≥70% bleeding sites, a near-significantly lower proportion of bleeding
interdental sites was observed in subjects using CPLE dentifrice combined with mouthwash compared
to those receiving SLS-free enzyme-containing dentifrice with alcohol-based EO mouthwash (21% vs.
33%, p = 0.05, Table 3). More importantly, this trend disappeared when the combined use of CPLE
dentifrice was compared to the use of SLS-free enzyme-containing dentifrice alone. Furthermore,
a near-significantly lower interdental bleeding level was seen when using CPLE dentifrice and
mouthwash compared to the combined use of SLS-free enzyme-containing dentifrice and alcohol-based
EO mouthwash. In contrast, no marked difference was observed in between-group pairwise
comparisons. A unique and statistically significant between-group difference was observed at 4 weeks
in the high-risk category between subjects receiving CPLE dentifrice with or without mouthwash.
In parallel, the decrease in bleeding interdental sites from T0 to T4 was more prominent in Group G+M
than that in Group G (−75% vs. −62%, p = 0.04).
No significant difference was observed between the different high-risk groups for the studied
variables and interproximal bleeding at T4 (Table 4).
Table 4. Distribution of variables at interdental site level and multivariate associations in the different
high-risk groups between the studied variables and interproximal bleeding at T4 (4 weeks) (n = 2273
interdentals sites from 100 subjects).
Variables
Subjects with≥70% of Bleeding
Sites at T4 50 Subjects
(1154 Interdental Sites)
Subjects with≥80% of Bleeding
Sites at T4 31 Subjects
(2273 Interdental Sites)
Subjects with≥90% of Bleeding
Sites at T4 15 Subjects
(344 Interdental Sites)
n OR a (95%-CI b) p-Value n OR a (95%-CI b) p-Value n OR a (95%-CI b) p-Value
Group G 297 1.0 199 47
Group Z 241 0.60 (0.18–1.78) 0.19 111 0.74 (0.28–2.23) 0.57 99 0.66 (0.13–3.36) 0.62
Group G + M 371 0.52 0.16–1.52) 0.07 200 0.49 (0.06–3.88) 0.16 100 0.30 (0.05–1.81) 0.19
Group Z + L 304 1.23 (0.42–3.21) 0.56 247 1.47 (0.48–4.16) 0.39 112 1.81 (0.37–8.90) 0.46
a Odds ratio. b Confidence interval.
4. Discussion
This study compared the effectiveness of a natural dentifrice containing Carica papaya leaf extract
to a commercially available SLS-free enzyme-containing dentifrice in reducing interdental gingival
bleeding. Since mouthwashes are typically used in conjunction with a mechanical cleaning regimen,
the effects of CPLE dentifrice used alone or with CPLE mouthwash versus an antimicrobial EO
mouthwash in combination with a non-antimicrobial dentifrice were also assessed.
To the best of our knowledge, this is the first clinical trial on the effects of the application of
natural extracts versus SLS-free enzyme-containing dentifrices against the interdental inflammatory
process. Our study reveals that CPLE dentifrice with or without mouthwash and SLS-free enzyme-
containing dentifrice with or without alcohol-based EO mouthwash significantly reduced interdental
inflammation at four weeks. Moreover, no significant difference was observed between the CPLE
dentifrice and the SLS-free enzyme-containing dentifrice whether or not they were combined with the
alcohol-based EO mouthwash. A dramatic decrease in interdental gingival bleeding appeared within
the four-week period in all groups. In the subjects with more than 70% bleeding, the combined use
of the CPLE dentifrice, both as a dentifrice and a mouthwash, showed a greater impact on bleeding
reduction than the use of the CPLE dentifrice alone.
Additionally, the two dentifrices tested significantly decreased interdental inflammation but
through different actions. Dentifrice containing enzymes stimulated natural salivary defenses.
The enzyme cascade leads to the production of hypothiocyanite and hydrogen peroxide, which could
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result in an increase in oxygen levels and an inhibition of the growth of anaerobic bacteria. This result
promotes a shift in the bacterial community, resulting in an increase in bacteria associated with
gum health and a concomitant decrease in those associated with periodontal disease, such as
Treponema spp [35]. No salient impact on interdental bleeding of the addition of mouthwash with
the dentifrice was observed in low or high-risk subjects. Although no formal conclusion was possible
given the non-significant differences, the results tended to be better with the use of the SLS-free
enzyme-containing dentifrice alone. Components of the alcohol solution may interact [36]. In the
present study design, it can be concluded that the interdental bleeding efficacy of a post-brushing
alcohol-based EO or CPLE mouthwash does not seem to be reduced under the influence of a
normal tooth brushing regimen with a dentifrice, whether or not the dentifrice contained enzymes or
CPLE powder.
The mechanisms of action of the CPLE dentifrice in the process of reducing interdental bleeding
have not yet been clearly identified. The various organs of this plant are rich in specific compounds.
For example, papain, an enzyme from papaya, is mainly harvested from the fruit latex, because it
does not accumulate to sufficient levels in other tissues [37]. Additionally, extraction solvents can
be concentrated in certain compounds to a greater or lesser extent. Polar solvents, such as water,
concentrate the most polar molecules, whereas highly apolar solvents, such as dichloromethane,
concentrate apolar molecules [38]. Enzyme effects are unlikely because the aqueous extraction by
decoction includes heating, which would unfold this type of molecule. Vascular effects have not
been documented in the papaya leaf to our knowledge. Previous studies have discovered several
activities from the leaves of Carica papaya linked to a few identified metabolites such as amino acids,
fatty acids, sugars and organic acids [39,40]. Therefore, the observed activities are probably related
to terpenes, which have been found to have antibacterial activity [41] and antifungal activity [42].
Another possibility is the large family of phenolic compounds that can have antioxidant activity [43–46],
antitumour activity [43,47] or immunomodulatory and antithrombocytopenic activity [48]. Similarly,
the biological effects of flavonoid secondary metabolites found in papaya leaves are evident.
The anti-inflammatory action (anti-TNF-alpha) of CPLE dentifrice could explain the global reduction
of gingival inflammation and thus the reduction of interdental bleeding. Anti-inflammatory activity
described by Erlund and colleagues is related to quercetin, hesperitin and naringenin present in the
leaves [49]. The anti-inflammatory mechanism of quercetin induces the activation of extracellular signal
kinase (ERK), c-Jun NH2-terminal kinase (JNK), c-Jun and nuclear factor-κB (NF-κB), or it induces an
increase in peroxisome proliferator-activated receptor (PPARγ) activity [50]. In addition, antimicrobial
activity has also been reported, including 3 Candida species and Gram-positive and Gram-negative
bacteria [51–53]. The final family of metabolites identified are the alkaloids, which have cytotoxic
activities [47,48,54,55], especially with certain cell lines. The literature also reveals antimicrobial
activities [37], particularly antifungal [42,56,57], antiparasitic [58–61], antibacterial [41,62–65] and
antiviral activities [66,67]. Finally, anti-inflammatory action has been attributed to the alkaloids of
papaya [68,69].
Some limitations of this study must be acknowledged. The stratification of the analyses of the
baseline interdental bleeding may have affected the comparability initially obtained between groups
after randomization. Nonetheless, groups did not statistically differ at the baseline compared to the
outcome, particularly among subjects presenting with a higher baseline interdental bleeding risk.
The subjects’ actual adherence to the assigned therapies was unknown. Nonetheless, a dramatically
significant decrease in bleeding at interdental sites was observed in all groups, suggesting a global
correct adherence level. This was a single-blind study, which could have impacted some of the
comparisons between groups. Nonetheless, we believe that our findings were minimally affected by
such bias, as our outcome was collected by trained investigators who were unaware of the subjects’
exposure. Further investigations, particularly observational studies, will be eventually needed to
confirm our conclusions in real-life settings.
Int. J. Environ. Res. Public Health 2018, 15, 2660 12 of 16
While the antimicrobial effect of only Listerine Cool Mint with a vehicle alcohol solution was
tested in combination with SLS-free enzyme-containing dentifrice, the results of our study may not be
extrapolated to all Listerine products [70]. For instance, alcohol-based EO mouth rinse penetrates and
kills microorganisms deeper and more effectively in plaque biofilm in typical exposure times when
compared to dentifrice chemotherapeutic agents [10].
Our results have clinical implications. CPLE dentifrice and mouthwash provide an efficacious
alternative to SLS-free enzyme-containing dentifrice with or without EO-containing mouthwash
when used as an adjunct to mechanical oral care. The data suggest that the CPLE dentifrice has
similar benefits and efficacy as the SLS-free enzyme-containing dentifrice alone or associated with
an alcohol-based EO mouthwash regarding interdental bleeding. Furthermore, our findings indicate
that the optimal benefit of the CPLE dentifrice in reducing interdental bleeding occurs when it is
used as both a dentifrice and a mouthwash. Given the current concerns regarding the safety of many
commercial types of dentifrice, the CPLE dentifrice could constitute an interesting natural alternative
to treat susceptible persons with interdental bleeding, particularly at an advanced stage of gingival
bleeding (>70%).
Nonetheless, our findings require confirmation in a less selected population or in patients
with periodontitis. Further comparisons against classical dentifrices and with other periodontitis
outcomes are also desirable. Our findings indicate that CPLE dentifrice/mouthwash used alone is
safe. However, a natural product does not inherently mean the absence of any adverse outcomes.
The benefit risk balance of CPLE dentifrice use should be investigated more thoroughly. Likewise,
the cost effectiveness ratio of CPLE dentifrice use must not be overlooked. Further research should be
done, especially on indications for long-term use and maintenance of a healthy oral microbiota as well
as special needs patients.
5. Conclusions
Finally, we conclude that the Carica papaya leaf extract dentifrice is effective when compared to
an SLS-free enzyme-containing dentifrice in the reduction of gingival bleeding and inflammation
and could constitute a valid parallel alternative to classical commercial dentifrices. This effect was
sustained with a continuing trend of reduction observed for tissue bleeding metrics. The addition of
alcohol-based EO mouthwash to the SLS-free enzyme-containing dentifrice did not show any clinical
benefit in terms of the reduction in interdental bleeding.
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